Wire · opportunities
Pfizer's TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 26 October 2026 · Fusion42 review
The FDA has expanded approval of Pfizer's TALZENNA plus XTANDI to treat men with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer with HRR gene mutations, based on Phase 3 TALAPRO-3 data showing a 52% reduction in risk of radiographic progression or death.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 26 Oct 2026 and 27 Oct 2026.
◆ ◆ The Wire takeaway
You can now target metastatic prostate cancer earlier with a new drug combo approved by the FDA. Biomarker testing for HRR mutations is key to accessing this expanded treatment window.
◆ Coverage
2 sources · first reported 26 Oct 2026 · latest 27 Oct 2026
◆ Related on Wire
◆ Topics